2 results
Approved WMOWill not start
To test the hypothesis that CLL depend on their cognate BCR ligands for growth and/or survival and that lowering specific antigenic pressure decreases the activation status of the leukemia clone resulting in a decrease in tumor burden.
Approved WMOCompleted
To assess safety, tolerability, and PK of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and Budigalimab in subjects with R/M HNSCC.